2023
CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. ELife 2023, 12 DOI: 10.7554/elife.87281.3.Peer-Reviewed Original ResearchImmune-related adverse eventsB-cell depletionB cellsT cellsSevere immune-related adverse eventsCTLA-4 antibody ipilimumabRegulatory T cell impairmentEffector memory T cellsAnti-TNF-alpha antibodyCTLA-4 deficiencyAnti-CTLA-4CD8 T cellsMemory T cellsRegulatory T cellsT cell impairmentPeripheral B cellsB cell lossReduced peripheral B cellsSeveral autoimmune diseasesKnock-in miceAntibody-drug conjugatesAntibody ipilimumabCombination immunotherapyAutoimmune cytopeniasCTLA-4CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. ELife 2023, 12: rp87281. PMID: 38127423, PMCID: PMC10735222, DOI: 10.7554/elife.87281.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsB-cell depletionB cellsT cellsSevere immune-related adverse eventsCTLA-4 antibody ipilimumabRegulatory T cell impairmentEffector memory T cellsAnti-TNF-alpha antibodyAnti-CTLA-4CTLA-4 deficiencyFoxP3<sup>+</sup> TregsCD8 T cellsT cell impairmentMemory T cellsRegulatory T cellsPeripheral B cellsB cell lossReduced peripheral B cellsSeveral autoimmune diseasesKnock-in miceAntibody-drug conjugatesAntibody ipilimumabCombination immunotherapyAutoimmune cytopenias
2022
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
Kidani Y, Nogami W, Yasumizu Y, Kawashima A, Tanaka A, Sonoda Y, Tona Y, Nashiki K, Matsumoto R, Hagiwara M, Osaki M, Dohi K, Kanazawa T, Ueyama A, Yoshikawa M, Yoshida T, Matsumoto M, Hojo K, Shinonome S, Yoshida H, Hirata M, Haruna M, Nakamura Y, Motooka D, Okuzaki D, Sugiyama Y, Kinoshita M, Okuno T, Kato T, Hatano K, Uemura M, Imamura R, Yokoi K, Tanemura A, Shintani Y, Kimura T, Nonomura N, Wada H, Mori M, Doki Y, Ohkura N, Sakaguchi S. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2114282119. PMID: 35140181, PMCID: PMC8851483, DOI: 10.1073/pnas.2114282119.Peer-Reviewed Original ResearchConceptsTumor TregsTumor immunityMAb treatmentTumor tissuesT cellsLong-lasting memoryCD4<sup>+</sup> regulatory T cellsPD-1 immune checkpoint blockadeCures of established tumorsInduce severe autoimmune diseaseSuppress antitumor immune responsesImmune responseT cell receptor clonotypesImmune checkpoint blockadeSystemic Treg depletionAntitumor immune responseConventional T cellsRegulatory T cellsTumor-associated antigensChemokine receptor CCR8Several autoimmune diseasesSecondary immune responseTreg depletionCheckpoint blockadePD-1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply